Enzyme's movement may be key to new cancer drugs

17-May-2018 - Revealing all the steps required to activate an enzyme called a protein kinase may identify new ways to target cancer, according to new University of Arizona-led research. Not only must the kinase have all needed parts in place, the enzyme must move in the correct manner and at the correct speed ...

arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers

03-Aug-2015 - arGEN-X N.V. and the Clinical Research Department of the University of Bern announce an exclusive license agreement enabling arGEN-X to develop and commercialize ARGX-110-based therapies to overcome treatment resistance mechanisms in hematologic tumors. The license agreement has arisen from a ...

Novartis drug Tasigna approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML

31-Aug-2010 - Swissmedic has granted approval for Tasigna® (nilotinib) 300 mg twice daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna is the first new therapeutic option for newly diagnosed patients since ...

FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients

22-Jun-2010 - Following a priority review, the US Food and Drug Administration (FDA) has approved Tasigna® (nilotinib) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. With this approval, Tasigna becomes the first new ...

Novartis drug Tasigna surpasses Glivec in slowing disease progression for newly diagnosed CML patients

04-Jun-2010 - Novartis announced 18-month results (median follow-up) showing that Tasigna® (nilotinib) significantly surpasses Glivec® (imatinib) in slowing disease progression in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. This ...

Novartis drug Tasigna receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia

Study results show Tasigna exceeds Glivecin every measure of efficacy in the trial including prevention of disease progression at 12 months

23-Feb-2010 - Novartis announced that Tasigna (nilotinib) has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. FDA priority review status is ...

Novartis drug Tasigna meets primary endpoint in pivotal trial against Glivec as first-line treatment in chronic myeloid leukemia

22-Oct-2009 - Novartis announced that Tasigna® (nilotinib) met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Glivec® (imatinib). Tasigna produced faster and deeper responses than Glivec when given as first-line therapy for adult patients with newly diagnosed ...

Innate Pharma reports phase II clinical data with IPH 1101 in oncology

21-Sep-2009 - Innate Pharma reports interim data from the Phase I/II clinical trial evaluating IPH 1101 in combination with rituximab1 in follicular non-Hodgkin’s lymphoma (“fNHL”) patients (study “IPH 1101-202”) and final data for the Phase IIa trial evaluating IPH 1101 in chronic myeloid leukemia (“CML”) ...

Novartis completes submissions in US and Europe for Glivec as treatment for four rare types of cancer

18-Apr-2006 - Novartis announced that it has submitted applications in the United States and Europe for Glivec® (imatinib) known as Gleevec® (imatinib mesylate) Tablets in the U.S. as treatment for four rare types of cancer. These filings underscore how cancers of different origin and location can share common ...

Genzyme Launches Key Test To Monitor Gleevec Resistance

Two Additional Personalized Medicine Tests Also Available

13-Feb-2006 - Genzyme Corporation announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec® (imatinib mesylate). Despite high response rates to Gleevec, approximately four to five percent of patients who were ...